

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

RECEIVED
SECRETARY OF THE SENATE
06 AUG 2006 PM 3:23

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name Novo Nordisk Inc			
2. Address <input type="checkbox"/> Check if different than previously reported 500 New Jersey Avenue NW Suite 350 Washington DC 20001			
3. Principal place of business (if different than line 2) Princeton NJ 08540 <small>City State/Zip or Country</small>			
4a. Contact Name Mr. Michael Mawby	b. Telephone number 202-626-4521	c. E-mail mmb@novonordisk.com	5. Senate ID # 28479
7. Client Name <input checked="" type="checkbox"/> Self Novo Nordisk Inc			6. House ID # 36903

TYPE OF REPORT 8. Year 2006 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____ 11. No Lobbying Activities

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>300,000</u></p> <p>14. REPORTING METHOD. Check box to indicate reporting method. See instructions for description of each method.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(e) Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>

Edit Form

Signature Michael Mawby Date 8/10/06

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

0000190434



Registrant Name Novo Nordisk Inc

Client Name Novo Nordisk Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code BUD - Budget/Appropriations (one per page)

16. Specific lobbying issues

FY 2007 Appropriations for diabetes-related activities including funding for the Diabetes Care Coalition and National Diabetes Education Program; related amendments and activities impacting patient safety and care.

17. House(s) of Congress and Federal agencies contacted None House Senate Other

HHS, CDC, NIDDK

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Michael	Mawby	Chief Government Affairs Officer
Steve	McGill	Associate Director, Government Affairs
Christopher	Porter	Senior Manager, Government Affairs
Christopher	McGowen	Manager, Government Affairs
Paige	Keener	Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date _____

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

0000190435

Registrant Name Novo Nordisk Inc

Client Name Novo Nordisk Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each** information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

Ensure the safety of drugs imported from abroad; ensure the safety of any biosimilar biologics that may eventually be approved for use in the United States; improve the detection, care and treatment of people with diabetes.

17. House(s) of Congress and Federal agencies contacted None House Senate Other

HHS, CMS, CDC, NIDDK, AHRQ

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Mawby	Chief Government Affairs Officer
Steve McGill	Associate Director, Government Affairs
Christopher Porter	Senior Manager, Government Affairs
Christopher McGowen	Manager, Government Affairs
Paige Keener	Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000190436

Printed Name and Title Michael Mawby, Chief Government Affairs Officer



Registrant Name Novo Nordisk Inc

Client Name Novo Nordisk Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

Implementation of the related provisions of the Deficit Reduction Act of 2005; Promotion of national legislation to change diabetes care; Patient Assistance Program-related legislation.

17. House(s) of Congress and Federal agencies contacted. None House Senate Other

HHS, CMS

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Mawby	Chief Government Affairs Officer
Steve McGill	Associate Director, Government Affairs
Christopher Porter	Senior Manager, Government Affairs
Christopher McGowen	Manager, Government Affairs
Paige Keener	Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000190437

Printed Name and Title Michael Mawby, Chief Government Affairs Officer



Registrant Name Novo Nordisk Inc

Client Name Novo Nordisk Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

Urging federal agencies to promote as widely as possible the coverage of diabetes screening; Promotion of diabetes-related and other preventive services available to Medicare beneficiaries; Regulations related to implementing diabetes-related provisions in the Deficit Reduction Act of 2005 and the Medicare Prescription Drug and Modernization Act; Other regulations impacting patient care, safety, and accessibility.

17. House(s) of Congress and Federal agencies contacted None House Senate Other

HHS, CMS, CDC, AHRQ

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Mawby	Chief Government Affairs Officer
Steve McGill	Associate Director, Government Affairs
Christopher Porter	Senior Manager, Government Affairs
Christopher McGowen	Manager, Government Affairs
Paige Keener	Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000190438

Printed Name and Title Michael Mawby, Chief Government Affairs Officer



Registrant Name Novo Nordisk Inc

Client Name Novo Nordisk Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each** information as requested. Attach additional page(s) as needed.

15. General issue area code HOM - Homeland Security (one per page)

16. Specific lobbying issues

S. 3678, Pandemic and All-Hazards Preparedness Act; S. 975, Project BioShield II Act of 2005 - Support broadening the approach to the selection of CBRN countermeasures to include broadly applicable agents

17. House(s) of Congress and Federal agencies contacted None House Senate Other

HHS, DHS

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Michael	Mawby	Chief Government Affairs Officer
Steve	McGill	Associate Director, Government Affairs
Christopher	Porter	Senior Manager, Government Affairs
Christopher	McGowen	Manager, Government Affairs
Paige	Keener	Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000190439

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

Registrant Name Novo Nordisk Inc

Client Name Novo Nordisk Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code CPT - Copyright/Patent/Trademark (one per page)

16. Specific lobbying issues

S 3818, Patent Reform Act of 2006; H.R. 2795, Patent Reform Act of 2005; related patent, trademark, and intellectual property issues.

17. House(s) of Congress and Federal agencies contacted None House Senate Other

PTO, Department of Commerce

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Mawby	Chief Government Affairs Officer
Steve McGill	Associate Director, Government Affairs
Christopher Porter	Senior Manager, Government Affairs
Christopher McGowen	Manager, Government Affairs
Paige Keener	Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000190440

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

